Notably, Niraparib, a potent PARP inhibitor, was authorized for advanced ovarian cancer regardless of homologous recombination (HR, a high-fidelity DNA repair mechanism) status, underscoring its broad therapeutic potential [3,4]. Here, PARP1 is linked to ovarian carcinoma.